Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pan-tumor × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 483 Carcinoma, Non-Small-Cell Lung 460 Prostatic Neoplasms 307 Multiple Myeloma 243 Neoplasms 235 Colorectal Neoplasms 223 Leukemia, Myeloid, Acute 199 Lung Neoplasms 195 Squamous Cell Carcinoma of Head and Neck 190 Neoplasm Metastasis 179 Carcinoma, Hepatocellular 173 Pancreatic Neoplasms 164 Melanoma 157 Triple Negative Breast Neoplasms 149 Ovarian Neoplasms 137 Recurrence 135 Glioblastoma 125 Lymphoma 124 Brain Neoplasms 122 Leukemia, Lymphocytic, Chronic, B-Cell 114 Stomach Neoplasms 109 Sarcoma 109 Precursor Cell Lymphoblastic Leukemia-Lymphoma 108 Lymphoma, Large B-Cell, Diffuse 107 Carcinoma, Renal Cell 106 Head and Neck Neoplasms 104 Myelodysplastic Syndromes 96 Small Cell Lung Carcinoma 88 Rectal Neoplasms 88 Lymphoma, Non-Hodgkin 88

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡